Drug Profile
BAY 1006578
Alternative Names: BAY-1006578Latest Information Update: 01 Mar 2019
Price :
$50
*
At a glance
- Originator Bayer HealthCare Pharmaceuticals
- Developer Life Molecular Imaging
- Class Diagnostic agents; Imaging agents
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Alzheimer's-disease in Finland (IV, Injection)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Alzheimer's-disease in Sweden (IV, Injection)